• Please log in or register to access this feature.

Liver Failure/Cirrhosis/Portal Hypertension

You have full text access to this OnlineOpen article

Prognostic value of Ishak fibrosis stage: Findings from the hepatitis C antiviral long-term treatment against cirrhosis trial†‡§

  1. James E. Everhart1,‖,*,
  2. Elizabeth C. Wright2,
  3. Zachary D. Goodman3,
  4. Jules L. Dienstag4,
  5. John C. Hoefs5,
  6. David E. Kleiner6,
  7. Marc G. Ghany7,
  8. A. Scott Mills8,
  9. S. Russell Nash9,
  10. Sugantha Govindarajan10,
  11. Thomas E. Rogers11,
  12. Joel K. Greenson12,
  13. Elizabeth M. Brunt13,
  14. Herbert L. Bonkovsky14,¶,
  15. Chihiro Morishima15,
  16. Heather J. Litman16,
  17. HALT-C Trial Group

Article first published online: 14 SEP 2009

DOI: 10.1002/hep.23315

Issue

Hepatology

Hepatology

Volume 51, Issue 2, pages 585–594, February 2010

Additional Information

How to Cite

Everhart, J. E., Wright, E. C., Goodman, Z. D., Dienstag, J. L., Hoefs, J. C., Kleiner, D. E., Ghany, M. G., Mills, A. S., Nash, S. R., Govindarajan, S., Rogers, T. E., Greenson, J. K., Brunt, E. M., Bonkovsky, H. L., Morishima, C., Litman, H. J. and HALT-C Trial Group (2010), Prognostic value of Ishak fibrosis stage: Findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology, 51: 585–594. doi: 10.1002/hep.23315

Author Information

  1. 1

    Division of Digestive Diseases and Nutrition, National Institutes of Health, Department of Health and Human Services, Bethesda, MD

  2. 2

    Office of the Director, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD

  3. 3

    Armed Forces Institute of Pathology, Division of Hepatic Pathology and Veterans Administration Special Reference Laboratory for Pathology, Washington, DC

  4. 4

    Gastrointestinal Unit (Medical Services), Massachusetts General Hospital and the Department of Medicine, Harvard Medical School, Boston, MA

  5. 5

    Division of Gastroenterology, University of California–Irvine, Irvine, CA

  6. 6

    Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD

  7. 7

    Liver Diseases Branch, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD

  8. 8

    Department of Pathology, Virginia Commonwealth University Medical Center, Richmond, VA

  9. 9

    Colorado GI Pathology, Centennial, CO

  10. 10

    Department of Pathology, University of Southern California at Rancho Los Amigos Medical Center, Downey, CA

  11. 11

    Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX

  12. 12

    Department of Pathology, University of Michigan Health System, Ann Arbor, MI

  13. 13

    Department of Pathology and Immunology, Washington University, St. Louis, MO

  14. 14

    Departments of Medicine and Molecular and Structural Biology and The Liver-Biliary-Pancreatic Center, University of Connecticut Health Center, Farmington, CT

  15. 15

    Virology Division, Department of Laboratory Medicine, University of Washington, Seattle, WA

  16. 16

    New England Research Institutes, Watertown, MA

  1. Carolinas Medical Center, Charlotte, NC

  1. ‖

    fax: 301-480-8300.

*Epidemiology and Clinical Trials Branch, Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, 2 Democracy Plaza, Room 655, 6707 Democracy Boulevard, MSC 5450, Bethesda, MD 20892-5450

  1. †

    The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health.

  2. ‡

    The HALT-C Trial was registered with clinicaltrials.gov (#NCT00006164).

  3. §

    Potential conflict of interest: Dr. Hoefs is on the speakers' bureau of Roche and Gilead. Dr. Greenson is a consultant for Roche, Millennium, and GlaxoSmithKline. Dr. Bonkovsky is a consultant for and advises Boehringer-Ingelheim and Novartis. He also advises and is on the speakers' bureau of Lundbeck Pharma. He received grants from Hoffmann-LaRoche, Merck, and Vortex.

  4. ‖

    fax: 301-480-8300.

Publication History

  1. Issue published online: 25 JAN 2010
  2. Article first published online: 14 SEP 2009
  3. Accepted manuscript online: 14 SEP 2009 12:00AM EST
  4. Manuscript Accepted: 3 SEP 2009
  5. Manuscript Received: 24 JUL 2009

Funded by

  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Institute of Allergy and Infectious Diseases (NIAID)
  • National Cancer Institute
  • National Center for Minority Health and Health Disparities
  • General Clinical Research Center
  • Clinical and Translational Science Center grants from the National Center for Research Resources
  • National Institutes of Health
  • Hoffmann-La Roche, Inc., through a Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (472K)

References

  • 1
    Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. HEPATOLOGY 2000; 31: 241–246.
  • 2
    Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy. HEPATOLOGY 2009; 49: 1017–1044.
  • 3
    Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. HEPATOLOGY 1981; 1: 431–435.
  • 4
    Batts KP. Acute and chronic hepatic allograft rejection: pathology and classification. Liver Transpl Surg 1999; 5(4 Suppl 1 ): S21–S29.
  • 5
    Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372–374.
  • 6
    Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. HEPATOLOGY 1996; 24: 289–293.
  • 7
    Ishak K, Baptista A, Bianchi L, Callea F, De GJ, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696–699.
  • 8
    Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, et al. Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials 2004; 25: 472–492.
  • 9
    Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008; 359: 2429–2441.
  • 10
    Goodman ZD. Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J Hepatol 2007; 47: 598–607.
  • 11
    D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44: 217–231.
  • 12
    Lagging LM, Westin J, Svensson E, Aires N, Dhillon AP, Lindh M, et al. Progression of fibrosis in untreated patients with hepatitis C virus infection. Liver 2002; 22: 136–144.
  • 13
    Zarski JP, Mc HJ, Bronowicki JP, Sturm N, Garcia-Kennedy R, Hodaj E, et al. Rate of natural disease progression in patients with chronic hepatitis C. J Hepatol 2003; 38: 307–314.
  • 14
    Ghany MG, Kleiner DE, Alter H, Doo E, Khokar F, Promrat K, et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003; 124: 97–104.
  • 15
    Ryder SD, Irving WL, Jones DA, Neal KR, Underwood JC. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut 2004; 53: 451–455.
  • 16
    Wilson LE, Torbenson M, Astemborski J, Faruki H, Spoler C, Rai R, et al. Progression of liver fibrosis among injection drug users with chronic hepatitis C. HEPATOLOGY 2006; 43: 788–795.
  • 17
    Levine RA, Sanderson SO, Ploutz-Snyder R, Murray F, Kay E, Hegarty J, et al. Assessment of fibrosis progression in untreated irish women with chronic hepatitis C contracted from immunoglobulin anti-D. Clin Gastroenterol Hepatol 2006; 4: 1271–1277.
  • 18
    Lawson A, Hagan S, Rye K, Taguri N, Ratib S, Zaitoun AM, et al. The natural history of hepatitis C with severe hepatic fibrosis. J Hepatol 2007; 47: 37–45.
  • 19
    Scheuer PJ, Lefkowitch JH. Cirrhosis: liver biopsy Interpretation. 7th ed. Philadelphia: Elsevier Saunders, 2006: 171–190.
  • 20
    Malik AH, Kumar KS, Malet PF, Jain R, Prasad P, Ostapowicz G. Correlation of percutaneous liver biopsy fragmentation with the degree of fibrosis. Aliment Pharmacol Ther 2004; 19: 545–549.
  • 21
    Desmet VJ, Roskams T. Reversal of cirrhosis: evidence-based medicine? Gastroenterology 2003; 125: 629–630.
  • 22
    Desmet VJ, Roskams T. Cirrhosis reversal: a duel between dogma and myth. J Hepatol 2004; 40: 860–867.
  • 23
    Colombo M, Del NE, de FR, De FC, Festorazzi S, Ronchi G, et al. Ultrasound-assisted percutaneous liver biopsy: superiority of the Tru-Cut over the Menghini needle for diagnosis of cirrhosis. Gastroenterology 1988; 95: 487–489.
  • 24
    Sherman KE, Goodman ZD, Sullivan ST, Faris-Young S. Liver biopsy in cirrhotic patients. Am J Gastroenterol 2007; 102: 789–793.
  • 25
    De HA, Loredo ML, Martinez-Rios MA, Gil MR, Kuri J, Cardenas M. Transjugular liver biopsy in 52 patients with an automated Trucut-type needle. Dig Dis Sci 1999; 44: 177–180.
View Full Article (HTML) Get PDF (472K)